Inflammatory Mediators in the Mesenteric Lymph Nodes, Site of a Possible Intermediate Phase in the Immune Response to Feline Coronavirus and the Pathogenesis of Feline Infectious Peritonitis? by Malbon, A. J. et al.
                          Malbon, A. J., Meli, M. L., Barker, E. N., Davidson, A. D., Tasker, S., &
Kipar, A. (2019). Inflammatory Mediators in the Mesenteric Lymph Nodes,
Site of a Possible Intermediate Phase in the Immune Response to Feline
Coronavirus and the Pathogenesis of Feline Infectious Peritonitis? Journal of
Comparative Pathology, 166, 69-86.
https://doi.org/10.1016/j.jcpa.2018.11.001
Peer reviewed version
License (if available):
CC BY-NC-ND
Link to published version (if available):
10.1016/j.jcpa.2018.11.001
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Elsevier at https://www.sciencedirect.com/science/article/pii/S0021997518302494?via%3Dihub . Please refer
to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
INFECTIOUS DISEASE 
 
Short Title: Immune Response to Feline Coronavirus 
 
Inflammatory Mediators in the Mesenteric Lymph Nodes, Site of a Possible 
Intermediate Phase in the Immune Response to Feline Coronavirus and the 
Pathogenesis of Feline Infectious Peritonitis? 
 
A. J. Malbon*,†, ‡, M. L. Meli‡, §, E. N. Barker¶, A. D. Davidson¥, S. Taskerǁ  
and A. Kipar*, ± 
*Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, Switzerland, 
†Graduate School for Cellular and Biomedical Sciences, Bern, Switzerland, ‡Center for 
Clinical Studies and §Clinical Laboratory, Vetsuisse Faculty, University of Zurich, 
Switzerland, ¶Langford Vets, Langford House, ǁBristol Veterinary School and ¥School of 
Cellular and Molecular Medicine, Faculty of Life Sciences, University of Bristol, UK and 
±Institute of Global Health, Faculty of Health and Life Sciences, University of Liverpool, UK 
 
 
 
Correspondence to: A. Kipar (e-mail: anja.kipar@uzh.ch).   
 
 
Summary 
Feline infectious peritonitis (FIP) is an almost invariably fatal feline coronavirus (FCoV)-
induced disease thought to arise from a combination of viral mutations and an overexuberant 
immune response.  Natural initial enteric FCoV infection may remain subclinical, or result in 
mild enteric signs or the development of FIP; cats may also carry the virus systemically with 
no adverse effect. This study screened mesenteric lymph nodes (MLNs), the presumed first 
site of FCoV spread from the intestine regardless of viraemia, for changes in the transcription 
of a panel of innate immune response mediators in response to systemic FCoV infection and 
with FIP, aiming to identify key pathways triggered by FCoV. Cats with and without FIP, the 
latter with and without FCoV infection in the MLN, were compared. Higher expression levels 
in FIP were found for toll-like receptors (TLRs) 2, 4 and 8. These are part of the first line of 
defence and suggest a response to both viral structural proteins and viral nucleic acid. 
Expression of genes encoding inflammatory cytokines and chemokines including interleukin 
(IL)-1β, IL-6, IL-15, tumour necrosis factor (TNF)-α, CXCL10, CCL8, interferon (IFN)-, 
IFN-β, and IFN-γ, was higher in cats with FIP, consistent with inflammatory pathway 
activation. Expression of genes encoding transcription factors STAT1 and 2, regulating 
signalling pathways, particularly of the interferons, was also higher. Among cats without FIP, 
there were few differences between virus-positive and -negative MLNs; however, TLR9 and 
STAT2 expression were higher with infection, suggesting a direct viral effect. The study 
provides evidence for TLR involvement in the response to FCoV. This could open up new 
avenues for therapeutic approaches. 
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Introduction 
Feline infectious peritonitis (FIP) is a well-known and widely distributed coronavirus-induced 
disease of felids.  With as yet no effective vaccine or viable treatment options, FIP is almost 
invariably fatal, and understanding the pathogenetic and immunological mechanisms involved 
in disease development is crucial to aiding chances of combatting FIP and identifying novel 
avenues for possible treatment.  
After initial enteric infection, feline coronavirus (FCoV) may spread beyond the 
intestine resulting in a monocyte-associated viraemia, with or without the development of 
FIP. In cases progressing to FIP, which may have a time lag of weeks to years, viral and host 
factors combine to turn an initial, usually subclinical, enteritis into an overt immune-mediated 
disease (Pedersen et al., 1981; Kipar and Meli, 2014). Much research has focussed on viral 
mutations and has partially elucidated the function of various viral proteins in the 
pathogenesis of FIP. The viral spike (S) protein gene has been of particular interest, and a 
switch from methionine (M) to leucine (L) at amino acid residue 1,058 (M1058L) has been 
strongly associated with a gain of virulence (Chang et al., 2012). A second switch from serine 
(S) to alanine (A) at amino acid residue 1,060 (S1060A) distinguished tissue-associated FCoV 
in a further small subset of FIP cases from FCoV shed with the faeces by healthy cats (Chang 
et al., 2012). These mutations have since been associated with systemic spread of FCoV, 
rather than providing proof of virulence (Porter et al., 2014; Barker et al., 2017; Felten et al., 
2017a) so the two forms are subsequently referred to here as ‘systemic’ and ‘enteric’ FCoV. 
Early experiments demonstrated that not all cats are susceptible to FCoV infection, 
even with known pathogenic strains (Pedersen and Boyle, 1980), indicating the importance of 
host genetic factors/immune mechanisms in disease development. More recently it was shown 
that cultured monocytes from different cats vary in their ability to sustain viral replication, 
again suggesting that there is a subset of animals who can resist disease (Dewerchin et al., 
2005; Tekes et al., 2010). Monocytes/macrophages are not the only cell type beyond 
enterocytes that may be infected by FCoV, but are also key cells in the innate immune 
defence system. They are able to detect pathogen associated molecular patterns (PAMPs), 
triggering a number of intracellular signalling pathways leading to activation of an antiviral 
state in the host (Abbas et al., 2017). Chief amongst these pathways are those triggered by 
engagement of toll-like receptors (TLRs); highly evolutionarily conserved, membrane-bound 
pathogen recognition receptors (PRRs) (Lester and Li, 2014). Their presence on both the cell 
surface membrane and internal membrane-bound vesicles allows detection of external and 
internal PAMPs; their ligands include those associated with viruses, bacteria and fungi 
(Arpaia and Barton, 2011). Downstream mediators include inflammatory cytokines and 
interferons which have been assessed in cats with FIP, with sometimes conflicting results 
(Dean et al., 2003; Kipar et al., 2006b). Interferons and the inflammatory cytokine interleukin 
(IL)-6 can activate members of the signal transducer and regulator of transcription (STAT) 
family with downstream effects on replication, differentiation or inflammatory potential 
(Aaronson and Horvath, 2002). Cats with a compromised immune system appear to be more 
susceptible to FIP, while, paradoxically, the lesions are caused by an excessive immune 
response (Pedersen, 1987, 2014; Kipar and Meli, 2014). This has been attributed, at least in 
part, to increased viral replication in immunosuppressed animals and, therefore, an increased 
likelihood of viral mutations occurring and accumulating (Poland et al., 1996).  
TLRs have been associated with susceptibility to many diseases, including chronic 
inflammatory, viral and more specifically coronaviral diseases (e.g. severe acute respiratory 
syndrome, SARS) (Dosch et al., 2009). Intriguingly though, both TLR stimulation and 
antagonism/knock-outs have contributed to exacerbation of disease in different contexts and 
there exists considerable crossover between receptors and their potential ligands (Arpaia and 
Barton, 2011). 
When FCoV is able to leave the intestine, the mesenteric lymph nodes (MLNs) are the 
presumed first site of viral spread, potentially representing the interface between local and 
systemic immune response; support for this assumption are FIP cases that present only with 
MLN lesions (Kipar et al., 1999). We therefore chose the MLN as our organ of interest, with 
the aim of comparing key mediators of the innate immune system between uninfected cats 
and FCoV-infected cats with and without FIP. We hypothesized that in addition to an 
excessive pro-inflammatory cytokine response, there would be a deficient interferon response, 
and aimed to gain an insight into which TLR pathways are involved in triggering this 
response. We also wished to further evaluate the presence and significance of previously 
published viral S gene variations and determine whether a connection with the host immune 
response could be detected.  
 
Materials and Methods 
Case Selection 
The study was undertaken on cats that had all been seen initially as patients at the university 
small animal clinics and local veterinary practices of Bristol, UK, or Zurich, Switzerland, and 
humanely destroyed with or without FIP for clinical reasons unrelated to this study (Table 1). 
A post-mortem examination was performed on each cat with owner consent and samples of 
MLN were collected into RNAlater® (Qiagen, Hombrechtikon, Switzerland) within 2 h of 
euthanasia and stored at –80°C until use. The Bristol cases form part of the University of 
Bristol FIP Biobank built up as a resource for multiple studies; many of these cases were 
utilized previously (Porter et al., 2014; Barker et al., 2017).   
Group 1 (G1) comprised of 40 control cats confirmed to not have FIP and with an 
alternate confirmed diagnosis (Tables 1A and 1B), and group 2 (G2) consisted of 30 cats 
confirmed to have FIP (Table 1C). A diagnosis of FIP was based on relevant clinical findings 
and compatible gross and/or histological lesions together with immunohistological 
demonstration of FCoV antigen-positive macrophages within typical lesions (Kipar et al., 
1998). The immunohistochemistry was carried out as previously described (Kipar et al., 
1998), using a mouse monoclonal primary antibody (clone FIPV3-70 SC 65653, Santa Cruz, 
Heidelberg, Germany). Based on the results of the reverse transcriptase quantitative 
polymerase chain reaction (RT-qPCR) for FCoV undertaken on the MLNs, group G1 was 
then subdivided into G1+ (FCoV-positive) and G1- (FCoV-negative). 
 
RNA Extraction and cDNA Synthesis 
RNA extraction was carried out using the RNeasy Plus Minikit® (Qiagen) according to the 
manufacturer’s protocol. Briefly, 30 mg of MLN tissue were disrupted in extraction buffer 
using a tissue homogenizer (Mixer-Mill 300, Retsch, Haan, Germany) for 40 sec at 30 Hz 
before on-column extraction and elution of RNA. As pilot tests revealed that significant 
genomic DNA contamination remained, an optional DNase step was included prior to use of 
the Superscript IV VILO® kit (ThermoFisher Scientific, Waltham, Massachusetts, USA) for 
cDNA synthesis, following the manufacturer’s instructions, in order to avoid possible 
interference with the RT-qPCR results. Starting RNA levels were equilibrated between 
samples to 400 ng/µl, using a NanoDrop 2000® (ThermoFisher Scientific). Samples were 
further diluted 1 in 20 prior to RT-qPCR. 
 
Reverse Transcriptase Quantitative Polymerase Chain Reaction 
TaqMan RT-qPCR was performed on an Applied Biosystems 7500 Fast PCR System® 
(ThermoFisher Scientific) using newly developed, or previously published, primer and probe 
protocols for: FCoV; feline TLR 1 to 9; STAT 1 to 3; interferon (IFN)-α, -β and -γ; IL-1β, -6, 
-10, -15, and -17; tumour necrosis factor (TNF)-α; CXC motif chemokine 10 (CXCL10); CC 
motif chemokine ligand 8 (CCL8); transforming growth factor (TGF)-β1; and glyceraldehyde 
3-phosphate dehydrogenase (GAPDH), as the reference gene (Table 2) (Leutenegger et al., 
1999). This gene was chosen based on previous experience in our laboratory and following 
reference gene comparisons during optimization. All primers and probes were manufactured 
by Microsynth (Balgach, Switzerland). The hydrolysis probes were labelled with a 5’ reporter 
dye FAM (6-carboxyfluorescein) and a 3’ quencher TAMRA (6-carboxy-
tetramethylrhodamine).  
Those primers and probes that were newly developed were designed using Primer 
Express® software (v3.0.1, Thermo Fisher Scientific) to span an exon–exon junction. These 
were tested for specificity by conventional PCR of a test sample, gel electrophoresis, 
sequencing of the resulting extracted band (Microsynth) and evaluation using NCBI BLAST. 
Conditions were as for RT-qPCR except for omission of the probe. Primer concentrations for 
this step were 900 nM. Varying primer/probe concentrations were then tested to determine the 
optimal efficiency and dynamic range as well as replicability using a sample dilution series. 
All final protocols (Table 2) had an efficiency >95%. Those previously published were tested 
again in our system, omitting the conventional RT-PCR step. Each reaction comprised 12.5 µl 
TaqMan Fast Universal Master Mix® (ThermoFisher Scientific), with 2.5 µl cDNA, primer 
and probe volumes as per Table 2, made up to 25 µl with RNase-free water. The thermal 
profile for all RT-qPCRs was: 50°C for 2 min, 95°C for 10 min, and 45 cycles of 95°C for 10 
sec, and 60°C for 1 min. All samples were run in duplicate and any samples with discordant 
results were repeated. Data collection occurred during the extension phase at 60°C. 
Appropriate controls were included in each run. 
The Applied Biosystems 7500 Software® v2.0.6 was used to visualize results and 
allocate a quantification cycle (Cq) to each sample, and the threshold was equilibrated 
between runs for each target.  
 
Viral Sequencing 
The particular codons of interest within the FCoV S gene were 1,058 and 1,060 (Chang et al., 
2012). With reference to the sequence used in the original paper, the mutations in question 
appear to be at positions 1,048 and 1,050 rather than 1,058 and 1,060 as previously described, 
and will be referred to subsequently by the former numbers.  
Following initial FCoV RT-qPCR, all positive samples not analysed for previous studies by 
Porter et al. (2014) or Barker et al. (2017) underwent additional conventional RT-PCR and 
Sanger sequencing targeting the S gene region of interest. PCR was performed using the 
previously published degenerate primers (Porter et al., 2014). Each reaction comprised 10 µl 
Phusion Flash Master Mix® (ThermoFisher Scientific), with 2 µl cDNA, 0.5 µM each of 
forward and reverse primers, made up to 20 µl with RNase-free water. Reactions were run on 
a T Professional® thermocycler (Biometra GmbH, Göttingen, Germany) with the following 
thermal profile: 98°C for 10 sec, 40 cycles of 98°C for 1 sec, 52°C for 5 sec, 72°C for 3 sec, 
followed by 72°C for 1 min. Appropriate controls were included in each run. 
The reaction product then underwent gel electrophoresis. Bands of appropriate size 
were extracted using the GeneJET Gel Extraction Kit® (ThermoFisher Scientific) and 
submitted for Sanger sequencing at a commercial laboratory (Microsynth). When no band was 
visible, the reaction was repeated using 50 cycles and the product was subjected to gel 
electrophoresis. Samples still appearing negative were cut out in the region of the expected 
band, purified and re-subjected to PCR. The bioinformatics software Geneious 9.1.7®, 
(Biomatters Limited, Silkeborg, Denmark) was used to map the resulting sequences to the 
reference gene FCoV C1Je (Accession number DQ848678) (Chang et al., 2012). 
 
Statistical Analysis 
Relative mRNA transcription levels were calculated using the comparative Cq method (Pfaffl, 
2001). The Cq of each target was first normalized to GAPDH as the endogenous reference 
(∆Cq) and then expressed relative to the G1 ∆Cq mean as the calibrator (2-∆∆Cq). For FCoV 
RT-qPCR results, the mean of G1+ was instead used as the calibrator (to allow for 
visualization graphically). 
The statistical programme SPSS Statistics v.25® (IBM, Armonk, New York, USA) 
was used for all analyses and graphical data presentation. Data were first assessed for 
normality using a Shapiro-Wilk test. As almost all data failed the test, so non-parametric 
measures were applied. A two-tailed Mann-Whitney test with a significance level of P  ≤0.05 
was used to compare results between groups for each target molecule. Firstly, cats with and 
without FIP (G1 versus G2) were compared, followed by comparisons between each of the 
three groups (G1-, G1+ and G2) in turn. Within G2, comparisons were made between cats 
with and without cavitary effusions and with and without histologically observed FIP lesions 
in the MLNs. Correlation between relative FCoV levels and inflammatory mediator gene 
expression levels, and also between individual inflammatory mediator gene expression levels, 
was analysed within G2 using a one-tailed Spearman’s rank test. Here a cut off of P ≤0.01 
was used, with P ≤0.05 indicating weak correlation.  
 
Results 
Feline Coronavirus Status within the Study Population 
Signalments of the cats are shown in Tables 1A–1C. All MLN samples from cats with FIP 
(G2) were positive for FCoV (n = 30). Of the 40 cats without FIP (G1), 10 (25%) also had a 
positive FCoV RT-qPCR result, these were assigned to a new sub-group (G1+). However, the 
relative FCoV load was clearly, and significantly, lower in G1+ than in G2 (Fig. 1). 
None of the G1 cats exhibited histological changes suggestive of FIP in any tissue 
examined, including the MLNs when available for histology (25 of 30 from G1- and seven of 
10 from G1+). Inflammation of other aetiologies was observed in the MLNs of two of the 30 
G1- cats and none of the G1+ animals. All G1 samples were also negative for FCoV antigen 
by immunohistochemistry.  
 
Association between Key Pathological Findings and Relative Viral Load in Mesenteric Lymph 
Nodes of Cats with Feline Infectious Peritonitis 
The MLNs were available for histological examination in 28 of the 30 cats with FIP. In 21 
cases (75%), these exhibited the typical pyogranulomatous lesions, with or without associated 
serosal lesions on the lymph node capsule (e.g. serofibrinous to granulomatous serositis). All 
samples with typical pyogranulomatous lesions also showed FCoV antigen in lesional 
macrophages (Figs. 2a, 2b). Seven MLNs had no typical lesions; among these was only one 
case (G2.19) in which FCoV antigen was detected, in low numbers of macrophages within the 
marginal sinus, suggesting an early lesion (Figs. 2c, 2d). There was no significant difference 
in FCoV load found between MLNs with and without lesions, although those with lesions had 
a tendency to higher FCoV levels (Fig. 1).  
Of the 30 cats with FIP, 22 exhibited effusions (Table 1C). These were not associated 
with a higher relative FCoV load in the MLNs in comparison with the cats without effusion (n 
= 6; data not available for two cats).  
 Association between Feline Infectious Peritonitis and Feline Coronavirus Status, Disease 
Features, Viral Load and Gene Expression of Immune Mediators  
In order to evaluate the effect of FCoV infection and FIP on target gene transcription, G1 and 
G2 were first compared with each other before comparisons between all three groups (G1+, 
G1- and G2). The assessed target genes are described below according to their positions in 
immune signalling pathways as first line receptors, inflammatory mediators or signal 
transducers. Detailed results are provided in Table 3. 
  
Toll-like Receptors: Relative TLR2, 4, and 8 gene transcription levels were significantly 
higher in G2 than G1. Within G1 there was no difference between virus-positive and virus-
negative MLNs for these TLRs; however, TLR9 gene expression, although not elevated in 
G2, was significantly higher in G1+ than in G1- (Fig. 3). 
In G2 cats, gene transcription levels were compared between MLNs with and without 
FIP lesions, and in relation to the presence of effusions. A significant difference was found 
only for TLR2 (higher expression in MLNs with lesions) (Fig. 3, Table 3); in contrast, TLR2 
expression appeared slightly lower in cats with effusions (Fig. 3). A possible trend not 
reaching significance was for a slightly higher TLR4 expression level in MLNs with lesions, 
while TLR3 and 9 gene expression levels were slightly lower (Fig. 3). Investigating this 
further, we found that TLR3 gene expression levels in G2 MLNs without lesions were also 
slightly higher than levels in G1 (which were similar to those in G2 MLNs with lesions), 
suggesting a potential negative regulation of TLR3 by FCoV (Fig. 3). 
  
Cytokines and Chemokines: Relative IL-1β, IL-6, IL-15, TNF-α, IFN-α, -β, -γ, CCL8 and 
CXCL10 gene transcription levels were all significantly higher in G2 compared with G1 (Fig. 
4). None of these showed any significant difference between G1+ and G1-. For most 
cytokines, G1+ and G1- clustered together; however, for IL-6, TNF-α and IFN-γ, G1+ 
appeared to cluster slightly between the other two groups (G1- and G2), suggesting a possible 
intermediate stage (Fig. 4). Between groups, the fold differences in the chemokine gene 
expression levels (CXCL10 and CCL8) were mainly in the range of 10–100×, while those for 
the pyrogenic cytokines (IL-1β, IL-6 and TNF-α) rarely exceeded 10×. IL-10, IL-17 and 
TGF-β gene transcription levels showed no intergroup differences (Fig. 4, Table 3). 
For IL-1β, IL-6, IFN-γ and CCL8, a possible trend towards increased transcription 
(not reaching significance) was observed in G2 MLNs with lesions compared with those 
without (Fig. 4). 
 
Signal Transducers and Activators of Transcription: STAT1 and 2 gene expression levels 
were significantly higher in G2 than G1. For both transcription factors, gene expression levels 
were also higher in G1+ than in G1-; significantly so for STAT2.  STAT3 gene expression 
levels were similar across all groups (Fig. 5). 
In G2, STAT2 gene expression levels were significantly higher in cats with effusions 
(Fig. 5, Table 3). For STAT1, there was an insignificant trend to be higher with effusions 
(Fig. 5). 
  
Correlation of Target Immune Mediators and Feline Coronavirus Load in Cats with Feline 
Infectious Peritonitis: The majority of gene targets elevated in G2 also showed significant 
positive correlation with relative viral load (Supplementary Table 1). These included TLR 2 
and 4, the cytokines IL-1β, IL-6, together with STAT2, CXCL10, CCL8, IFN-β and IFN-γ (P 
≤0.01). TLR8 and IFN-α gene expression showed weaker correlation (P ≤0.05), while 
STAT1, TGF-β, and TNF-α gene expression showed no correlation, and TLR9 a weak, 
although significant, negative correlation (Table 4). 
Expression of genes encoding IL-6, IL-17 and STAT3, a ‘holy trinity’ of 
autoimmunity (Camporeale and Poli, 2012), was significantly correlated despite the latter two 
not showing any correlation with FCoV.  
 
Partial S Gene Sequencing 
Of the 40 cats shown by RT-qPCR to carry FCoV in their MLNs, 38 had analyzable S gene 
sequences following conventional PCR. From the remaining two cats (G1+ cats 1 and 6) it 
was not possible to obtain samples of sufficient quality even after repeated attempts (Table 
1B).   
Of the 30 cats with FIP, one was infected with FCoV serotype 2 for which the 
previously described S gene sequence characterization is not applicable (Herrewegh et al., 
1998; Barker et al., 2017). Twenty-six MLN samples contained virus that encoded leucine 
(M1048L) (cDNA sequence TTG, CTG or TTA). The remaining three cats encoded 
methionine at codon 1,048 (cDNA sequence ATG). The results are shown in Table 1C. Of the 
eight sequences obtained from the G1+ cats, all encoded leucine (M1048L). Of the three cases 
encoding methionine at codon 1,048, two encoded alanine at the codon 1,050 (S1050A), 
whilst the third encoded serine (Table 1B). 
The small methionine group size (n = 3) including only one cat that carried the 
‘enteric’ virus (M1048, S1050) was not considered valid for statistical comparison with the 
leucine group, ‘systemic’ virus. Instead, individual cases were plotted, revealing the 
methionine group to fall within the range of the leucine group for every target, including 
FCoV load (Fig. 1).  
 
Discussion 
As predicted from previous studies, the results of the present investigation confirm the 
complex effect of FCoV on the immune system in association with FIP. The disease is caused 
by an exaggerated immune response to FCoV, but it is well known that cats can also carry 
FCoV systemically without developing FIP (Meli et al., 2004). Here we have assessed some 
of the key mediators of the innate immune response, focussing on the MLN, the most likely 
first site of infection beyond the intestine and one of the main sites of viral persistence in 
experimentally infected healthy animals (Kipar et al., 2010). By comparing FCoV-positive, 
lesion-free MLNs from cats affected by diseases other than FIP, with both FCoV-negative 
cats without FIP and cats with FIP, we aimed to separate the direct viral effects from the host 
effects contributing to FIP in a natural setting. 
FIP presents as a spectrum of disease with variable duration rather than as a discrete 
clinical picture; as such the pathological features also vary. This was reflected by variation in 
organ involvement and presence of effusions in our case cohort. We therefore also wanted to 
assess whether the inflammatory mediator production in the MLNs showed any correlation 
with the form of disease. Although vascular permeability is, to a large extent, cytokine 
mediated (Takano et al., 2011), and we found upregulation of cytokine genes with a role in 
vascular permeability in the FIP cases, the inflammatory mediator gene expression profile of 
the MLNs differed only minimally between cats with and without effusions. This suggests 
that the MLN is unlikely to make a large systemic contribution to vascular permeability. 
Similarly, Safi et al. (2017) evaluated inflammatory mediators within peripheral blood 
mononuclear cells of FIP cats with and without effusions and found little consistent pattern to 
distinguish those with effusions from those without. Both studies therefore provide further, 
although indirect, support that vascular endothelial growth factor, which was previously 
shown to correlate with the degree of effusion in FIP, is key to this phenomenon (Takano et 
al., 2011). Interestingly, the presence or absence of histological FIP lesions was not correlated 
with many significant differences between mediator gene expression. Alongside this, and 
surprisingly, although FCoV levels appeared higher in association with lesions, they were not 
significantly so. This may partly explain the lack of significant differences in mediator gene 
expression. Additionally, it cannot be entirely excluded that the area of the MLN sampled for 
RNA extraction failed to correlate with the histological findings in some cases. An alternative 
explanation for the lack of significant differences between gene expression for most mediators 
in MLNs, while many exhibit higher overall levels in FIP, would be that systemic stimulation 
to upregulate inflammatory mediators is more relevant than local or lesion-specific 
stimulation. Finally, as trends were occasionally observed when cases with and without 
effusions and MLN lesions were compared, the lack of significance may also be due to the 
small group sizes once subgroups were created, which was a limitation of this study.  
The MLNs of cats without FIP had significantly lower viral loads than their 
counterparts from cats with FIP. This confirms previous findings in natural infection, where 
cats with FIP were reported to carry higher viral loads in haemopoietic and lymphoid tissues, 
including MLNs, than asymptomatic FCoV-infected cats (Kipar et al., 2006a).  Without the 
disease, however, the presence or absence of FCoV in the MLN seems not to influence the 
transcription level of most of our target immune mediators. This would indicate that, in the 
main, the host response has a greater influence than any direct viral effect. Still, there were 
exceptions. Even among those mediators not attaining significance, IFN-γ, IL-6 and TNF-α 
showed a trend towards higher gene expression levels in FCoV-positive MLNs. This suggests 
at least a modest direct viral effect; it may have been masked by low group numbers, 
requiring a larger sample size to confirm or refute. Another study limitation was the 
composition of the groups. As all were field cases it was not possible to control for 
confounding factors, e.g. ensuring control cases were free of any inflammatory processes, that 
FIP cases were at similar disease stages, and that cats were initially subject to the same FCoV 
infection pressures. 
Inflammatory cytokines have been previously studied in FIP, with conflicting results, 
possibly dependent on variations in disease form between animals included in the different 
studies, and/or the type of sample/organ evaluated. TNF-α gene transcription, for example, 
was found to be decreased in the MLNs of cats with FIP compared with FCoV-free specific 
pathogen-free cats, while IL-1β gene expression was elevated (Kipar et al., 2006b). In the 
present study, gene expression for all three pyrogenic cytokines (IL-1β, IL-6 and TNF-α) was 
upregulated in the MLNs in FIP, as well as that for IL-15 (a stimulator of lymphocyte 
proliferation). We also found significantly higher transcription levels for the monocyte-
recruiting chemokines CXCL10 and CCL8, which have both been found to be upregulated in 
Crandell–Rees feline kidney cells after in-vitro FCoV infection (Harun et al., 2013), 
indicating a mechanism of monocyte recruitment as a direct viral effect. Our results confirm 
their relevance in vivo with recruitment of monocytes as the infected cell type being a 
potential amplifying step that is worthy of further investigation. The increase in inflammatory 
cytokine gene transcription supports the observation that an overexuberant inflammatory 
response is a key factor in the development and progression of FIP. Expression of the gene 
encoding the anti-inflammatory cytokine IL-10 was, in contrast, not upregulated in FIP, 
implying there was no local brake on the inflammatory process. This is in line with previous 
findings, where IL-10 expression was higher in the spleen of healthy FCoV-infected cats, but 
not in the MLN (Kipar et al., 2006b). Gene expression for the interferons was also higher in 
FIP, IFN-γ being one of the cytokines to show an intermediate level in infected asymptomatic 
cats in our study. These type I and II interferons have major antiviral roles in the innate 
immune system. IFN-γ in particular has been of interest in FIP as levels of this potentially 
protective cytokine tend to be low in the peripheral blood of diseased animals and host gene 
polymorphisms have been identified which may contribute to resistance against the disease 
(Gelain et al., 2006; Hsieh and Chueh, 2014). Similarly to the apparent lack of impact of 
mediator levels on the presence of lesions or effusions in FIP, this suggests that MLN IFN 
production has a more local effect.  
TLRs have been used for targeted therapy against a number of diseases in human 
medicine, both with adjuvants and inhibitors; however, veterinary medicine lags behind in 
this respect (Hennessy et al., 2010; Klingemann, 2018). Here we identified increased gene 
expression levels of TLRs 2, 4, 8 and 9 with FIP and FCoV infection, respectively, indicating 
a possible role for these molecules in FIP and hence identifying them as potential targets for 
FIP control. Assessment at the protein level would be a useful avenue for further 
investigations; however, this is particularly challenging in feline studies owing to the lack of 
availability of appropriate antibodies.  In most mammals, TLRs 2 and 4 are located on the cell 
membranes, while TLRs 8 and 9 are found in intracytoplasmic vesicles, most commonly in 
professional antigen presenting cells (Lester and Li, 2014). TLR2, together with TLRs 1, 6 
and 10, comprise the TLR1 family (Roach et al., 2005). These latter three receptors arose 
through evolutionary gene duplication (Hughes and Piontkivska, 2008, Hennessy et al., 
2010). TLR2 is able to signal as a heterodimer with any of its co-family members in order to 
allow a wider range of antigen recognition. It is typically responsible for detecting bacterial 
and fungal components (Beutler, 2009).  TLR2 has been linked to detection of the SARS-CoV 
S protein in vitro (Dosch et al., 2009); its upregulation in FIP could indicate that the FCoV S 
protein is also able to act as a ligand.  
TLR4 classically detects lipopolysaccharide; however, one study linked it to 
protection against murine coronavirus, as TLR4-deficient mice were found to exhibit greater 
susceptibility to murine hepatitis virus infection. The precise mechanism was not established 
in that case, but it involved inflammatory cell influx in the TLR4-deficient mice (Khanolkar et 
al., 2009). No such protective effect was observed in our study, despite upregulation of TLR4 
gene expression in the MLNs in association with FIP, although its individual effect in this 
case cannot be separated from the mediator milieu. 
TLR9 gene expression was not elevated in the MLNs of cats with FIP, but was instead 
increased in the FCoV-positive MLNs of cats without FIP. Considering that a previous in-
vitro study found reduced viral replication when TLR9 was stimulated with a synthetic CpG 
ligand prior to FCoV infection (Robert-Tissot et al., 2012), the increased gene expression in 
FCoV-infected cats without FIP could indicate that TLR9 has a protective effect, which may 
even have helped prevent the development of disease. Stimulation by co-infectious agents 
could therefore also be hypothesized to be protective against FIP. Along these lines, co-
infection must also be considered a possible alternative explanation for the raised TLR 2 and 
4 gene expression levels, as these TLRs are more typically associated with bacterial 
infections. Enteric coronavirus infection or the generalized inflammatory state induced by FIP 
may have increased the permeability of the intestinal barrier to microorganisms. The resulting 
TLR stimulation would therefore not be virus induced. A third alternative is the upregulation 
of TLR 2 and 4 by endogenous ligand stimulation, reported as a response to alarmin release 
from damaged cells (van Beijnum et al., 2008). This alternative also fits with upregulation of 
TLR2 gene expression in lesional MLNs compared with non-lesional MLNs in FIP. 
From their known ligands, TLRs 3, 7 and 8 would be predicted to be triggered in 
infection by FCoV as it is a ssRNA virus (triggering TLRs 7 and 8), possessing a double-
stranded RNA intermediate replicating phase (triggering TLR3) (Arpaia and Barton, 2011). 
That no upregulation occurs for TLR3 and TLR7 with FIP suggests either the lack of an 
appropriate trigger  (TLR 7 and 8 are known to show differing, if overlapping, specificity, and 
dsRNA intermediate replicates are a minority of the viral RNA present; Jensen and Thomsen, 
2012), or that the virus is able to inhibit TLR transcription. SARS-CoV is known to inhibit 
both TLR 3 and 7 signalling via papain-like protease activity (PLpro) (Li et al., 2016). This 
mechanism may also contribute in FCoV infection, but would be expected to affect the 
signalling pathways rather than the TLR mRNA levels directly.  In cats with FIP, we observed 
slightly lower TLR3 gene transcription in MLNs with typical FIP lesions, as compared with 
MLNs without lesions, down to the levels seen in MLNs from cats without FIP. This could 
indicate a general systemic stimulus to upregulate TLR3 in FIP, which is counteracted locally 
by viral inhibition of TLR3. Prior stimulation of TLR3 has also been shown in vitro to 
contribute to defence against murine coronavirus via type I interferon induction 
(Mazaleuskaya et al., 2012), so is another potential avenue for future FIP research. A larger 
sample population, in particular with larger numbers of systemically infected cats without 
FIP, might have revealed significant intergroup differences for TLR3. 
The STAT transcription factors are a key part of the antiviral pathways, mediating 
many downstream IFN effects (Aaronson and Horvath, 2002). They have also been linked to 
other coronavirus infections (e.g. STAT1 knock-out mice show a markedly increased 
susceptibility to SARS-CoV, while avian infectious bronchitis coronavirus uses STAT1 
inhibition of IFN responses) (Frieman et al., 2010; Kint et al., 2015). STAT 1 and 2 gene 
transcription levels correlated with type II and I interferon transcription levels, respectively, in 
our study, while in virus-positive MLNs of cats without FIP, STAT 1 and 2 levels (the latter 
significantly so), as well as IFN-γ levels, lay between the other two groups. This shows that 
the levels of IFNs and their downstream transcription factors are closely linked. Interestingly, 
STAT2 gene expression levels were significantly higher in the MLNs of cats with FIP and 
with effusions, a finding that cannot be readily explained. STAT2 has been linked to IL-6 
upregulation, which itself has been linked to increased vascular permeability (Maruo et al., 
1992; Nan et al., 2018); however, the IL-6 gene was not upregulated in our cohort, suggesting 
that responsibility lies with another pathway. 
The results of our S gene codon mutation analysis add weight to recent findings that 
the M1058L mutation (referred to as M1048L in the present study due to re-evaluation of the 
reference sequence) is likely to contribute to systemic spread, but does not itself confer 
pathogenicity (Chang et al., 2012; Porter et al., 2014). This indicates that further host and/or 
viral factors are required for the development of FIP or, more precisely, the activation of 
virus-infected monocytes as a prerequisite to set off FIP vasculitis (Kipar and Meli, 2014). 
Most likely owing to the low viral RNA levels within the MLNs of cats without FIP, 
obtaining an adequate sequence from this group proved problematic. Other researchers 
experienced similar problems, often finding that FCoV RT-PCR-positive samples from cats 
without FIP were not amenable to sequencing (Felten et al., 2017b). The lack of FCoV 
antigen expression in these cats was not unexpected and reflects the rarity of infected cells 
and/or the low virus load in infected cells; this is in line with the results of a previous study 
that found only rare positive macrophages in the MLNs of experimentally persistently-
infected cats (Kipar et al., 2010). 
It was not possible to compare statistically the induced immune response of viruses 
showing S protein amino acid variations (codons 1,048 and 1,050) as only one cat had the 
‘enteric’ form.  
The future outcome of our FCoV infected cats without FIP, had they not succumbed to 
other diseases, is unknown, as is the contribution of yet to be defined viral factors. These cats 
may have remained carriers or have been demonstrating a transitional phase to later 
development of disease. However, based on our observations, activation of genes encoding 
TLRs 2, 4 and 8 in MLNs is associated with a negative outcome (i.e. FIP), while carrier 
animals upregulated the gene encoding TLR9.  IFN-γ, and particularly STAT2 with its myriad 
opportunities to direct cell fate, displayed intermediate levels of upregulation in the MLNs of 
the carrier/transitional group, not associated with widespread increase in mediators of 
inflammation.  
This study is only the start of determining the extent of involvement of PRRs in FIP; 
the downstream effects of these transcriptional alterations must be further investigated. 
However, our results reinforce the need for a balanced immune response against the virus, 
with the hypothesis that the moderate response in cats without FIP is part of the key to 
controlling the virus; when this balance is lost the animal may be at risk of succumbing to 
disease. 
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Figure Legends 
Fig. 1. Boxplots demonstrating relative levels of FCoV transcription in G1+ and G2. The 
amount of FCoV was calculated by 2-∆∆Cq, using fGAPDH as the internal reference gene and 
expressed as an n fold difference relative to the G1+ mean as a calibrator. The boxes depict 
the median and interquartile (IQ) range with whiskers extending to the highest and lowest 
values which are within 1.5 × the IQ range. Outliers beyond this are individually marked. The 
three columns of individual crosses within G2 depict the three variations in the viral S protein 
at codons 1,048 and 1,050 respectively. From left to right: L, leucine at 1,048 (‘systemic’ 
virus); M&A, methionine and alanine (‘systemic’ virus); M&S, methionine and serine 
(‘enteric’ virus). 2E+/- and 2L+/- represent relative FCoV levels amongst MLN of cats with 
and without effusions/lesions. 
 
Fig. 2. Examples of MLNs with and without lesions from cats with FIP. (a, b) Case G2.5. (a) 
Focal pyogranulomatous inflammation with central necrosis (*).  HE. (b) Viral antigen 
expression is seen in abundant intact lesional macrophages.  IHC.  (c, d) Case G2.19.  (c) 
Reactive hyperplasia with expansion of the marginal sinus by macrophages (*). HE.  (d) 
Some of the latter are FCoV antigen-positive.  IHC.  
 
Fig. 3. Boxplots of relative levels of TLR gene expression in each group.  The amount of 
target was calculated by 2-∆∆Cq, using fGAPDH as the internal reference gene and expressed 
as an n fold difference relative to the G1 mean as a calibrator. The boxes depict the median 
and interquartile (IQ) range with whiskers extending to the highest and lowest values, which 
are within 1.5 × the IQ range. Outliers beyond this are individually marked. * marks 
significant differences between individual groups (P ≤0.05) or, where joined by a bar, 
between G1 as a whole and G2. 2E+/- and 2L+/- represent relative gene expression levels 
among MLNs of cats with and without effusions/lesions. 
 
Fig. 4.  Boxplots of relative levels of cytokine and chemokine gene expression in each group.  
The amount of target was calculated by 2-∆∆Cq, using fGAPDH as the internal reference gene 
and expressed as an n fold difference relative to the G1 mean as a calibrator. The boxes depict 
the median and interquartile (IQ) range with whiskers extending to the highest and lowest 
values, which are within 1.5 × the IQ range. Outliers beyond this are individually marked. * 
marks significant differences between individual groups (P ≤0.05) or, where joined by a bar, 
between G1 as a whole and G2. 2E+/- and 2L+/- represent relative gene expression levels 
amongst MLNs of cats with and without effusions/lesions. 
 
Fig. 5. Boxplots of relative levels of STAT gene expression in each group.  The amount of 
target was calculated by 2-∆∆Cq, using fGAPDH as the internal reference gene and expressed 
as an n fold difference relative to the G1 mean as a calibrator. The boxes depict the median 
and interquartile (IQ) range with whiskers extending to the highest and lowest values, which 
are within 1.5 × the IQ range. Outliers beyond this are individually marked. * marks 
significant differences between individual groups (P ≤0.05) or, where joined by a bar, 
between G1 as a whole and G2. 2E+/- and 2L+/- represent relative gene expression levels 
amongst MLNs of cats with and without effusions/lesions. 
 
Table 1: Signalment, pertinent histological and immunohistological findings, and Sanger sequencing results of all cases. 
A. Group 1-: Cats without FIP and without evidence of systemic FCoV infection as determined by RT-qPCR on the mesenteric lymph node. 
  Breed Age Sex Diagnosis 
MLN 
Histology IH (FCoV Ag) 
1 Ragdoll 4 y MN Congestive heart failure Normal - 
2 Bengal 11 y MN Colonic adenocarcinoma Normal ND 
3 DSH adult FN DCM, chronic kidney disease Follicular hyalinosis - 
4 DSH adult MN Acute myeloid leukaemia Leukaemia - 
5 Birma 1 y MN Hippocampal necrosis Normal - 
6 House cat 14 y MN Haemorrhage in brain Follicular hyalinosis ND 
7 DSH 8 y MN Chemodectoma Normal - 
8 Birman 13 y   Pyothorax and  pneumonia Neutrophilic and histiocytic inflammation - 
9 DSH 6 y MN Astrocytoma Normal to reactive hyperplasia - 
10   10 y MN Diabetes mellitus Reactive hyperplasia and amyloidosis - 
11 DSH 12 y   Aplastic anaemia Neutrophilic inflammation - 
12 DSH 6 y   Diarrhoea, suspected torovirus ND ND 
13 DLH 8 y   Gastric lymphoma Normal - 
14 DSH 5 y MN Suppurative meningitis Mild depletion - 
15 DSH 3 y MN Lymphocytic cholangiohepatitis Normal to reactive hyperplasia ND 
16 DSH 2 y MN Hepatitis and pyelonephritis Reactive hyperplasia and sinus histiocytosis - 
17 DSH 4 y FN Granulomatous rhinitis & encephalitis ND ND 
18 DSH 8 y FN Chronic enteropathy ND ND 
19 DSH 1 y FN Poxviral pneumonia ND ND 
20 DSH 4 y FN Hepatic encephalopathy ND ND 
21 Ragdoll 3 y MN Hypertrophic cardiomyopathy ND ND 
22 DSH 13 y FN Focal intestinal necrosis Normal ND 
23 DSH   FE Behavioural Normal to reactive hyperplasia - 
24 DSH 3 y FN Invasive meningioma Normal to reactive hyperplasia - 
25 Maine Coon 9 y   Meningioencephalitis Normal - 
26 DSH 5 y FN Pulmonary adenocarcinoma Tumour emboli ND 
27 Devon Rex 8 y   Inflammatory bowel disease Normal - 
28 DSH 9 y MN Multicentric lymphoma Reactive hyperplasia - 
29 DSH 10 m MN Hypertrophic cardiomyopathy Reactive hyperplasia and sinus histiocytosis - 
30 Bengal 7 y FN Jejunal constriction Follicular depletion - 
 
MLN, mesenteric lymph node; IH, immunohistology; Ag, antigen; DSH, domestic short hair; DLH, domestic long hair; blank, data not available; F/M(E/N), female/male 
(entire/neutered); DCM, dilated cardiomyopathy; ND, not done;  -, negative. 
 
B. Group 1+: Cats without FIP but with evidence of systemic FCoV infection as determined by FCoV RT-qPCR on the mesenteric lymph node. 
  
Breed Age Sex Diagnosis 
MLN 
  Histology 
IH         
(FCoV Ag) 
Sequencing 
codon 
1048 
codon 
1050 
1 Maine Coon 1 y   Pleural effusion (FCoV RT-qPCR -ve) ND ND Not possible 
2 DSH 3y MN Lethargy, weight loss, anaemia ND ND TTG Leu ND   
3 DSH 10 y MN Diabetes mellitus Reactive hyperplasia with collagen scars - CTG Leu ND   
4 Ragdoll 4 m ME Severe interstitial pneumonia Normal to reactive hyperplasia - CTG Leu TCC Ser 
5 Havana 4 y FN Nasal lymphoma ND ND TTG Leu TCT Ser 
6 DSH 10 y FN Round cell neoplasia Sinus histiocytosis - not possible 
7 DSH 8 y MN Pleural effusion (FCoV RT-qPCR -ve) Normal - TTG Leu ND   
8 DSH 18 y FN Chronic kidney disease Sinus histiocytosis ND TTG Leu TCT Ser 
9 DSH 10 y MN Lymphoma Normal - CTG Leu ND   
10 DSH - FE Anaesthetic death Normal to reactive hyperplasia - CTG Leu ND   
 
MLN, mesenteric lymph node; IH, immunohistology; Ag, antigen; DSH, domestic short hair; blank, data not available; F/M(E/N), female/male (entire/neutered); -, negative; 
ND, not done. 
C. Group 2: Cats with FIP. 
  Breed Age Sex Effusion 
MLN 
FIP lesions 
IH           
(FCoV Ag) 
Sequencing 
Codon 
1048 
Codon 
1050 
1 DSH 10 y FN + (A) Necrotising and pyogranulomatous + TTG Leu TCT Ser 
2 Norwegian Forest 8 m MN - Necrotising and pyogranulomatous and lymphoplasmacytic + CTG Leu TCT Ser 
3   4 m ME + (A) Granulomatous + ATG Met GCT Ala 
4   1.5 y MN + (A) Pyogranulomatous + TTG Leu TCA Ser 
5 Maine Coon 1 y MN + (A) Pyogranulomatous and lymphoplasmacytic + TTG Leu TCC Ser 
6 DSH 6 m MN + (A, P) Granulomatous + TTG Leu TCT Ser 
7 DSH 4 m FE + (M) Granulomatous + TTG Leu TCT Ser 
8 BSH 6 y MN + (A) Pyogranulomatous + TTG Leu TCC Ser 
9 Persian 5 m FE + (A) Pyogranulomatous + TTG Leu TCT Ser 
10   3 y   + (A) Granulomatous + TTG Leu ND   
11 Burmese 3 m ME + (T) Necrotising and granulomatous + TTG Leu ND   
12 Abyssinian 4 m FE + (A) Pyogranulomatous + TTG Leu ND   
13 DSH -   + (T) ND ND TTG Leu ND   
14 DSH 5 m   + (A, T) Necrotising and pyogranulomatous + TTG Leu ND   
15 Siamese 1 y   + Pyogranulomatous + CTG Leu TCC Ser 
16 BSH 10 m MN + Sinus histiocytosis - TTG Leu TCC Ser 
17 DSH 2 y MN + Reactive hyperplasia - TTG Leu TCT Ser 
18 Siamese 3 y MN + (A, T) Normal - c/tTG Leu TCT Ser 
19 Birman 12 y MN + (M) Reactive hyperplasia + TTG Leu TCC Ser 
20 BSH 1 y FN + (A, T) Pyogranulomatous + ATG Met TCC Ser 
21 DSH 2 y MN - Granulomatous + ATG Met GCC Ala 
22 Oriental 3 y ME - Granulomatous + TTG Leu TCC Ser 
23 Birman 8 m ME - ND ND TTA Leu TCA Ser 
24 Ragdoll 10 m FN   Necrotising and granulomatous + TTG Leu TCC Ser 
25 BSH 2 y MN + (A) Necrotising and pyogranulomatous + TTG Leu TCC Ser 
26 DSH 6 m FE - Normal - CTG Leu TCT Ser 
27 DSH 1 y   + (A) Reactive hyperplasia - FCoV Type II 
28 DSH 4 m     Reactive hyperplasia - TTG Leu TCC Ser 
29  DSH  7 m   - Pyogranulomatous + TTG Leu ND   
30 DSH   ME + (A) Pyogranulomatous + TTG leu ND   
 
MLN, mesenteric lymph node; IH, immunohistology; Ag, antigen; DSH, domestic short hair; blank, data not available; BSH, British long hair; F/M (E/N), female/male 
(entire/neutered); +, positive/present; -, negative/absent; A, abdominal; P, pericardial; M, multicavitary; T, thoracic; ND, not done; Leu, leucine; Ala, alanine; Met, 
methionine; Ser, serine. Nucleotide bases in lower case indicate a mixed infection. 
Table 2 Primer and probe sequences used for RT-qPCR and conventional RT-PCR 
Gene 
Reference or 
accession number 
Primer and probe sequences (5'-3') where not 
previously published 
PCR product 
length (base 
pairs) 
GAPDH, IL-10 Leutenegger et al., 1999 
 
 
 FCoV (RT-qPCR) Gut et al., 1999 
   FCoV (conventional) Porter et al., 2014 
   TLR1, 2, 4, 5 ,6, 7, 9 Ignacio et al., 2005 
 
 
 
TLR3, 8, IL-15, IFN-α, -β 
Robert-Tissot et al., 
2011 
   IL-1β, IL-6, TNF-α Kipar et al., 2001 
 
 
 TGF-β Taglinger et al.,  
 
 
 IL-17 XM_006931816.1 F-16 ACTTCATCCATGTTCCCATCACT 126 
  
R-141 CACATGCTGAGGAAAATTCTTGTC 
 
  
P-83 CATTCCCACAAAATCCAGGATGCCC 
 STAT1 XM_006935443 F-1649 TTGACCTCGAGACGACCTCTCT 135 
  
R-1783 GCGGGTTCAGGAAGAAGGA 
 
  
P-1686 CTCCAATGTCAGCCAGCTCCCGAGT 
 STAT2 XM_003988893 F-1182 GCCCAGGTCACGGAGTTG 122 
  
R-1303 ACAGTGAACTTGCTCCCTGTCTT 
 
  
P-1212 CTGCACAGAGCCTTTGTGGTAGAAACCC 
 STAT3 XM_006940361.2 F-1626 GCCAGTTGTGGTGATCTCCAA 133 
  
R-1758 TTGATCCCAGGTTCCAATCG 
 
  
P-1696 CTGACCAACAACCCCAAGAACGTGAACTTT 
 CCL8  XM_003996558 F-95 GGCCACCTTCAGCATCCA 82 
  
R-176 CCCTTTGACCACACTGAAGCA 
 
  
P-121 CTCAGCCAGGTTCAGTTTCCATCCCA 
 CXCL10 XM_003985274.3 F-386 TGCCATCATTTCCCTACATTCTT 78 
  
R-463 CAGTGGTTGGTCACCTTTTAGGA 
 
  
P-411 CAAGCCCTAATTGTCCCTGGATTGCAG 
 IFN-γ NM_001009873.1 F-214 TGGAAAGAGGAGAGTGATAAAACAA 122 
  
R-335 TCCTTGATGGTGTCCATGCT 
     P-284 ACCTGAAAGATGATGACCAGCGCATTCAA   
Accession number, NCBI accession number; F, forward primer and start site; R, reverse primer and start 
site; P, probe and start site. All final reactions contained equivalent F and R concentrations of 900 nM and 
250 nM for P, with the exception of FCoV RT-qPCR, 300 and 250 nM; FCoV conventional, 500nM; TGF-
β, 200 and 50 nM; STAT3, 600 and 250 nM, respectively. 
Table 3: Results of statistical comparisons between groups of cats, using a two-tailed Mann-Whitney test 
 
Statistical comparison between FIP group 
  
G1 vs G2 G1- vs G1+ G1+ vs G2 
Effusions   
present vs 
absent 
MLN lesions 
present vs 
absent 
FCoV 0.000* 0.000* 0.000* 0.764 0.071 
TLR1 0.610 0.914 0.794 0.643 0.533 
TLR2 0.000* 0.724 0.002* 0.259 0.048* 
TLR3 0.569 0.724 0.656 0.682 0.189 
TLR4 0.019* 0.794 0.022* 1.000 0.208 
TLR5 0.053 0.508 0.396 0.806 0.756 
TLR6 0.859 0.286 0.469 0.764 0.228 
TLR7 0.059 0.770 0.272 0.427 0.568 
TLR8 0.012* 0.246 0.015* 0.566 0.435 
TLR9 0.991 0.031* 0.140 0.764 0.189 
STAT1 0.000* 0.315 0.000* 0.052 0.466 
STAT2 0.000* 0.017* 0.000* 0.017* 0.717 
STAT3 0.260 0.569 0.414 0.764 1.000 
IFN-α 0.041* 1.000 0.077 0.604 0.499 
IFN-β 0.004* 0.770 0.036* 0.566 0.604 
IFN-γ 0.000* 0.131 0.003* 0.806 0.249 
IL-1β 0.026* 0.432 0.031* 0.849 0.272 
IL-6 0.001* 0.209 0.177 1.000 0.208 
IL-10 0.296 0.469 0.939 0.604 0.272 
IL-15 0.019* 0.794 0.039* 0.53 0.376 
IL-17 0.440 0.528 0.286 0.723 1.000 
TGF-β 0.430 0.508 0.396 0.978 0.678 
TNF-α 0.004* 0.432 0.346 0.309 0.405 
CXCL10 0.000* 0.396 0.000* 0.441 0.263 
CCL8 0.000* 0.177 0.000* 0.46 0.071 
* indicates significance level of p ≤ 0.05. In the first three columns the second group of the comparison is significantly 
higher in all cases (e.g. for G1 vs G2, G2 levels are higher). In the FIP columns the value of the ‘present’ group is in 
both cases higher than in the ‘absent’ group. 
Table 4: Summary of Spearman’s rank one-tailed correlation results within the FIP group, showing immune mediators with significant results. 
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FCoV ● ↑↑ ↑↑ ↑ ↑  ↑↑  ↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑    ↑↑ ↑↑ 
TLR2 ↑↑ ● ↑↑ ↑↑   ↑ ↑↑  ↑↑ ↑↑ ↑↑ ↑↑     ↑↑ ↑↑ 
TLR4 ↑↑ ↑↑ ● ↑↑  ↑ ↑↑ ↑↑  ↑ ↑↑ ↑↑ ↑↑ ↑ ↑↑   ↑↑ ↑↑ 
TLR8 ↑ ↑↑ ↑↑ ●    ↑↑    ↑↑ ↑↑     ↑ ↑ 
TLR9 ↓    ● ↑↑ ↑ ↑↑        ↑↑ ↑   
STAT1   ↑  ↑↑ ● ↑↑ ↑↑    ↑ ↑ ↑ ↑  ↑↑ ↑↑ ↑ 
STAT2 ↑↑ ↑ ↑↑  ↑ ↑↑ ● ↑↑  ↑ ↑ ↑↑ ↑↑ ↑↑ ↑  ↑↑ ↑↑ ↑↑ 
STAT3  ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ●  ↑  ↑↑ ↑↑  ↑↑ ↑ ↑↑ ↑↑ ↑↑ 
IFN-α ↑       ↑ ● ↑↑ ↑↑ ↑ ↑  ↑  ↑  ↑ 
IFN-β ↑↑ ↑↑ ↑    ↑ ↑ ↑↑ ● ↑↑  ↑  ↑  ↑↑ ↑ ↑↑ 
IFN-γ ↑↑ ↑↑ ↑↑    ↑ ↑ ↑↑ ↑↑ ● ↑↑ ↑↑  ↑  ↑ ↑↑ ↑↑ 
IL-1β ↑↑ ↑↑ ↑↑ ↑↑  ↑ ↑↑ ↑↑ ↑  ↑↑ ● ↑↑  ↑↑ ↑ ↑↑ ↑↑ ↑↑ 
IL-6 ↑↑ ↑↑ ↑↑ ↑↑  ↑ ↑↑ ↑↑ ↑ ↑ ↑↑ ↑↑ ●  ↑  ↑↑ ↑↑ ↑↑ 
IL-15 ↑  ↑   ↑ ↑↑       ●    ↑↑ ↑ 
IL-17   ↑↑   ↑ ↑ ↑↑ ↑ ↑ ↑ ↑↑ ↑  ●  ↑   
TGF-β     ↑↑   ↑    ↑    ● ↑   
TNF-α     ↑ ↑↑ ↑↑ ↑↑ ↑ ↑↑ ↑ ↑↑ ↑↑  ↑↑ ↑ ● ↑ ↑ 
CXCL10 ↑↑ ↑↑ ↑↑ ↑  ↑↑ ↑↑ ↑↑  ↑ ↑↑ ↑↑ ↑↑ ↑↑   ↑ ● ↑↑ 
CCL8 ↑↑ ↑↑ ↑↑ ↑   ↑ ↑↑ ↑↑ ↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑     ↑ ↑↑ ● 
↑↑, positive correlation at a significance level of p≤0.01; ↑, positive correlation at a significance level p≤0.05; ↓, negative correlation at a 
significance level of p≤0.05 
 
